A chikungunya vaccine, developed by Themis Bioscience GmbH will be assessed for safety and efficacy in Phase II trials in Puerto Rico from August 2017.
Browsing: Emerging Disease > Chikungunya
Human mobility and globalization have brought new invasive species to other countries. In terms of environment and nature, some of…
Researchers have analyzed the clinical characteristics of Zika infection in Canadian travelers returning from the Americas, discovering that severe complications might be more common than previously estimated.
Researchers have identified a crucial mechanism by which the chikungunya virus infects host cells and mediates disease severity. This could present a future treatment target for both chikungunya and related viruses.
In this review the author looks at the progress of vaccine development towards mosquito-borne viral diseases, such as Zika and chikungunya.